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Abstract
Background: Prenatal exposure to infection is a recognized environmental risk factor for neuropsychiatric disorders
of developmental origins such as autism or schizophrenia. Experimental work in animals indicates that this link is
mediated by maternal immune activation (MIA) involving interactions between cytokine-associated inflammatory
events, oxidative stress, and other pathophysiological processes such as hypoferremia and zinc deficiency. Maternal
administration of the viral mimic polyriboinosinic-polyribocytidylic acid (poly(I:C)) in mice produces several
behavioral phenotypes in adult offspring of relevance to autism spectrum disorder (ASD) and other
neurodevelopmental disorders.
Methods: Here, we investigated whether some of these phenotypes might also present in juveniles. In addition, given
the known immunomodulatory and neuroprotective effects of vitamin D, we also investigated whether the
co-administration of vitamin D could block MIA-induced ASD-related behaviors. We co-administered the hormonally
active form of vitamin D, 1α,25 dihydroxy vitamin D3 (1,25OHD), simultaneously with poly(I:C) and examined (i) social
interaction, stereotyped behavior, emotional learning and memory, and innate anxiety-like behavior in juveniles and (ii)
the levels of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α in maternal plasma and fetal brains.
Results: We show that like adult offspring that were exposed to MIA, juveniles display similar deficits in social approach
behavior. Juvenile MIA offspring also show abnormal stereotyped digging and impaired acquisition and expression of
tone-cued fear conditioning. Importantly, our study reveals that prenatal administration of 1,25OHD abolishes all these
behavioral deficits in poly(I:C)-treated juveniles. However, prenatal administration of vitamin D had no effect on
pro-inflammatory cytokine levels in dams or in fetal brains suggesting the anti-inflammatory actions of vitamin D are
not the critical mechanism for its preventive actions in this ASD animal model.
Conclusions: This work raises the possibility that early dietary supplementation with vitamin D may open new avenues
for a successful attenuation or even prevention of neurodevelopmental disorders following maternal inflammation
during pregnancy.
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Background
Prenatal exposure to infection is a recognized environ-
mental risk factor for neuropsychiatric disorders of devel-
opmental origins. This epidemiological association has
been most widely studied in the context of schizophrenia
[1]. Since the first report in 1971 [2], however, evidence
has accumulated to suggest that prenatal infection also is
a risk factor for autism spectrum disorder (ASD) [3, 4].
For example, studies of the Danish health registry show
that from more than one million children born between
1980 and 2005 there was an almost threefold increase in
the rate of ASD diagnosis in children born to mothers
who were hospitalized for viral infection during pregnancy
[5]. A similar (albeit somewhat less strong) association has
been found in a large Swedish nationwide register-based
birth cohort born 1984–2007 with follow-up through
2011 [6]. Experimental work in animals indicates that this
link is mediated by maternal immune activation (MIA) in-
volving an interplay between cytokine-associated inflam-
matory events [7–9], oxidative stress [10], and other
pathophysiological processes such as hypoferremia [11]
and zinc deficiency [12]. The centrality of inflammatory
cytokine production to MIA phenotypes is supported by
the findings that blocking the actions of pro-inflammatory
cytokines such as IL-1β, IL-6, or IL-17a in the pregnant
maternal host is capable of preventing the long-term brain
and behavioral consequences of prenatal immune activa-
tion [7, 9, 13, 14]. Similarly, over-expression of the anti-
inflammatory cytokine IL-10 prevents the emergence of
multiple behavioral and pharmacological abnormalities
typically seen after prenatal immune challenge [8].
Currently, the most widely used animal model for MIA is
gestational exposure to the viral mimic, polyriboinosinic-
polyribocytidylic acid (poly(I:C)). Poly(I:C) is a synthetic
analog of double-stranded RNA that induces a cytokine-
associated viral-like acute phase response in maternal and
fetal compartments, including the fetal brain [15]. Initially
developed in the context of preclinical schizophrenia re-
search [16–18], more recent research shows that this model
also reproduces an array of adult behavioral phenotypes
with relevance to ASD, including impairments in social
interaction and species-specific communication, stereo-
typed behaviors, and altered emotional learning and behav-
ior [9, 19–21]. Hence, poly(I:C)-based MIA models provide
experimental support for epidemiological findings linking
prenatal immune challenges with increased risk of ASD [2,
5, 6]. One limitation of current MIA models, however, is
that they mostly focused on ASD-related phenotypes once
the offspring reached early adulthood, whereas overt ASD
symptoms typically emerge in children.
Another epidemiologically valid developmental risk fac-
tor for later psychiatric disease is developmental vitamin
D (DVD) deficiency [22]. Besides its role in schizophrenia
etiology, there is a growing body of evidence linking
vitamin D deficiency with autism [23]. Birth cohort studies
have provided evidence that maternal vitamin D defi-
ciency is associated with a range of later autism-related
outcomes including impaired language development [24]
and cognitive development in offspring [25]. Most re-
cently, we have shown that low levels of vitamin D at birth
are associated with increased incidence of autism in chil-
dren [26]. Low vitamin D would also appear to be preva-
lent in children diagnosed with autism [27].
In addition to its classical role in calcium and bone
homeostasis, vitamin D has major immunomodulatory roles
associated with inflammation [28]. For instance, vitamin D
interferes with pro-inflammatory transcription factors and
signaling pathways, regulates the expression of pro-
inflammatory enzymes, and modulates cytokine gene expres-
sion, protein production, and signaling. More specifically,
vitamin D inhibits the production of pro-inflammatory cyto-
kines such as IL-6 or TNF-alpha in monocytes via the inhib-
ition of p38 MAP kinase [29], and it downregulates the
expression of IL-6 mRNA [30]. Vitamin D also reduces the
release of IL-1β in stimulated peripheral blood mononuclear
cells (PBMC) [31]. Developmental vitamin D deficiency has
further been shown to induce persistent alterations in im-
mune function, by increasing central immune organ size and
inducing a pro-inflammatory lymphocyte phenotype [32].
Therefore, inflammatory factors produced early in brain
development either directly, by inducing MIA, or indirectly,
by the maternal absence of a potent anti-inflammatory fac-
tor such as vitamin D may, represent a convergent pathway
towards developmental brain abnormalities and psychiatric
conditions later in life. Initial evidence for this hypothesis
stems from previous observations showing prenatal
poly(I:C)-induced MIA, and developmental vitamin D defi-
ciency in rodents produce an overlapping spectrum of
long-term behavioral abnormalities and early molecular
changes in the fetal brains [33–37].
The objectives for this study were threefold. (a) We
sought to verify whether autism-related behavioral defi-
cits induced by poly(I:C) are present at a more transla-
tionally relevant prepubertal age. (b) Given the anti-
inflammatory properties of vitamin D, the present study
was designed to investigate whether use of calcitriol, [1α,
25-dihydroxy vitamin D3 (1,25OHD)], the hormonally
active form of vitamin D, could prevent poly(I:C)-in-
duced behavioral dysfunctions relevant to ASD, includ-
ing deficits in social interaction, stereotyped behavior,
innate anxiety, and emotional learning. (c) Does
1,25OHD block the poly(I:C)-induced inflammatory
response in either dams or fetal brains?
Methods
Animals
C57BL6/N mice were used throughout the study. Female
and male breeders were obtained from Charles River
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Laboratories (Sulzfeld, Germany) at the age of 12–
14 weeks. Breeding began after 2 weeks of acclimatization
to the animal holding rooms, which were temperature-
and humidity-controlled (21 ± 1 °C, 55 ± 5%) facilities
under a reversed light-dark cycle. All animals had ad
libitum access to water and standard rodent chow (Kliba
3430, Kaiseraugst, Switzerland) which contains 1000-IU
cholecalciferol/kg.
Experimental groups
For the purpose of the maternal manipulations, C57BL6/N
female mice were subjected to a timed-mating procedure
as described previously [18]. Pregnant dams on gestation
day (GD) 9 were first injected subcutaneously with
1,25OHD (VitD) or vehicle (VEH) and were then immedi-
ately injected intravenously with either poly(I:C) (POL) or
saline solution (CON) as described below. GD 9 in the
mouse roughly corresponds to human gestational weeks 4
to 5 in terms of limbic neurogenesis (http://translatingti-
me.net/translate). This gestational window was selected
based on epidemiological studies suggesting that the first
trimester of human pregnancy may be associated with
maximal vulnerability for viral infection-mediated neurode-
velopmental disorders such as ASD [5] and schizophrenia
[38]. Thus, the pregnant dams were divided into four treat-
ment groups: CON/VEH, CON/VITD, POL/VEH, POL/
VITD. For behavioral studies, pups remained with the same
dam until weaning at 21 days of age, after which littermates
of the same sex were caged separately and maintained in
groups of 3–5 animals per cage. Each experimental group
on postnatal day (PND) 35 consisted of offspring derived
from multiple independent litters (at least six in each pre-
natal treatment condition) and included male subjects only
to circumvent interpretative limitations arising from hor-
monal fluctuations in females [39]. For cytokine studies, a
separate cohort of 18 GD9 pregnant dams received the ap-
propriate solution and were decapitated 4 h after injection
in order to collect dam blood and fetal brains for cytokine
measurements (see below).
Administration of 1,25OHD or vehicle
1,25OHD (VitD) (solid powder, Calbiochem, EMD
Millipore, Cat No 679101-50UG) was dissolved in abso-
lute ethanol to 100 ng/μl as a stock solution. The stock
was aliquoted and was stored in sterile tubes at −80 °C
until further use. Subsequently, drug delivery solution
was prepared as follows: 4 μl VitD (100 ng/μl) or abso-
lute ethanol were added into 2 ml of corn oil to make a
drug solution for delivery. The solution was vortexed to
disperse VitD in the corn oil. The dosing was calculated
with the formula 400 ng/kg/2 ml, such that the final
injection volume in microliter was equal to 2 ml/kg dam
body weight. The VitD or vehicle solution was adminis-
tered subcutaneously in the neck region.
In pilot studies, we ensured the chosen dose would not
induce any adverse effects on pup development or behav-
ior as adults. To this end, 8 dams received vehicle and 9
dams VitD (400 ng/kg). These dams produced 50 and 55
offspring. In developing pups, we assessed body weight
(g), crown-rump length (cm), eye opening, ear opening,
ear folding, fur development, tooth eruption, and righting
reflex on PND 8, 11, 14, 17, and 21 as outlined previously
[40]. VitD had no effect on any of these measures (see
Additional file 1). We also assessed dam weight gain,
water and food consumption, and fecundity. Again there
was no effect of VitD (see Additional file 2). We also
assessed two behaviors in these offspring as adults. For
both spontaneous locomotion in an open field (Additional
file 3) and anxiety-like behavior in an elevated plus maze
(Additional file 4) there was no effect of VitD.
Maternal immune activation during pregnancy
Poly(I:C) (potassium salt; Sigma-Aldrich, Buchs, St.
Gallen, Switzerland; 5 mg/kg; calculated based on the
pure form) or vehicle (saline) was dissolved in sterile
pyrogen-free 0.9% NaCl (vehicle) solution to yield a final
concentration of 1 mg/ml and was administered intra-
venously into the tail vein under mild physical con-
straint. The dose of poly(I:C) was selected based on
previous dose–response studies [18].
Behavioral studies
Behavioral testing was conducted in prepubertal off-
spring, between PND 30-40. For behavior, two different
cohorts of animals were used. The use of two different
cohorts served to minimize potential confounding fac-
tors associated with prolonged behavioral testing, but
more importantly, to ensure that testing age remained in
the prepubertal period. The first cohort was used for
assessing innate anxiety behavior and social approach
behavior, and the second cohort was used for assessing
stereotypical behavioral and emotional learning and
memory. For both cohorts, the number of subjects in
each of the four experimental groups was n = 8. All be-
havioral testing was performed in the dark phase of the
light-dark cycle.
Elevated plus maze test
The elevated plus maze test served as a test for innate
anxiety-like behavior. The apparatus was made of Plexi-
glas painted in gray and consisted of four equally spaced
arms (5 × 30 cm2) radiating from a square center (5 ×
5 cm2). One pair of opposing arms was enclosed with
opaque walls (height: 15 cm) except for the side adjoin-
ing the central square. The remaining two arms were ex-
posed with a parameter border (height: 3 mm) along the
outer edges. The maze was elevated 70 cm above floor
level and was positioned in a testing room with diffused
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lighting (approximately 20 Lux in open arm and 10 Lux
in closed arm). A digital camera was mounted above
the plus maze, captured images at a rate of 5 Hz and
transmitted them to a PC running the EthoVision
(Noldus Technology, Wageningen, The Netherlands)
tracking system.
A test session began by placing the animal into the cen-
ter zone with it facing one of the closed arms. It was then
left to explore freely for 5 min before being returned to
the home cage. After each trial, the apparatus was cleaned
with water and dried before a new trial began. The (i) rela-
tive (percent) time spent in the open arms, (ii) distance
moved in the open arms, and (iii) total distance moved in
the open and closed arms during the entire 5-min test
period were analyzed in order to index anxiety-related be-
havior. The percent time spent in the open arms was
calculated using the formula [(time spent in the open
arms)/(time spent in all arms) × 100].
Social interaction
Social interaction was assessed using a social approach
test in a modified Y-maze as previously outlined [21]. The
apparatus was in the form of a Plexiglas Y-maze consisting
of three identical arms (50 × 9 × 10 cm, length × width ×
height), radiating from a triangle center zone (each side
8 cm). Two of the three arms contained rectangular wire
grid cages, the third arm served as the start zone.
Animals were first habituated to the apparatus by be-
ing allowed to explore the maze for 10 min on 2 days
(day 1 and 2), which served to reduce novelty-induced
locomotor hyperactivity. During the test day (day 3), one
wire cage contained an unfamiliar C57BL/6N mouse
(same sex as test mouse), and the other one contained a
“dummy object” made of black LEGO™ (Billund,
Denmark). The allocation of the objects (live mouse ver-
sus dummy object) was counterbalanced across arms
and treatments. At the beginning of a test session, the
animal was placed at the end of the start arm and was
allowed to explore freely for 5 min. A camera, mounted
above the maze, captured images and transmitted them
to the EthoVision tracking system (Noldus, The
Netherlands) to assess general locomotor activity. Social
interaction was defined as nose orientation towards the
wire cage within a 6-cm interaction zone adjacent to the
wire cage. This was assessed by a trained experimenter
who was blind to the treatment. After 5 min, the animal
was removed and the apparatus was cleaned. Social
interaction was assessed by analyzing the relative explor-
ation time between the unfamiliar mouse and the inani-
mate dummy object using the following formula: % time
spent with mouse = ([time spent with mouse]/[time
spent with mouse] + [time spent with inanimate
object]) × 100.
Marble burying test
Stereotyped behavior was assessed using the marble
burying test [41]. The test was performed as described
in a study by Thomas and colleagues [42] with small
modifications. Clean cages (27 × 16.5 × 12.5 cm) were
filled with a 2-cm layer of chipped cedar wood bedding.
Males were habituated to this cage for 10 min and then
were returned to the home cage. Twenty colored glass
marbles (15 mm diameter) were then gently laid on top
of the bedding, equidistant from each other in a 4 × 5 ar-
rangement. Animals were placed back into the testing
cage, and the number of marbles buried (criteria for a
buried marble was >50% marble covered by bedding ma-
terial) in 10 min recorded.
Cued Pavlovian fear conditioning
Emotional learning and memory were assessed using a
cued Pavlovian fear conditioning test. The apparatus
(Coulbourn Instruments, Allentown, PA, USA) has been
fully described before [18]. It comprised two sets of test
chambers to provide two distinct contexts (context A and
B). The first set of chambers (context A) included operant
chambers that were installed in ventilated, sound-
insulated chests (72 cm wide × 45 cm long × 45 cm high).
Each chamber of context A comprised a transparent rect-
angle measuring 14 × 16 × 30 cm (wide × long × high) and
was fitted with a parallel grid shock floor (16 parallel bars,
spaced 2 cm apart from each other; E10–18RF; Coulbourn
Instruments), through which scrambled shocks could be
delivered. Scrambled foot shocks provided the uncondi-
tioned stimulus (US). Illumination inside the chambers of
context A was provided by a house light (2.8 W) posi-
tioned on the panel wall. The second set of chambers
(context B) comprised cylinder transparent enclosures
(16 cm diameter × 30 cm high), which rested on white
Plexiglas floor instead of parallel grid floors. They were
placed in ventilated, sound-insulated chests (72 × 45 ×
45 cm) that were illuminated by an infrared light source
instead of visible light. A fully automated algorithm was
used to detect and quantify the freezing response as vali-
dated previously [43].
The test of cued Pavlovian fear conditioning included
3 phases, which were each separated by 24 h: The first
day was conditioning (day 1, context A): following an
initial habituation period of 6 min, the animals were ex-
posed to three conditioning trials involving pairings be-
tween a conditioned stimulus (CS) and the US in
context A. The CS was a 2.9-kHz tone measuring
86 dBA, which co-terminated with a 1-s, 0.3 mA foot
shock US. The intertrial interval between each CS and
US trial was 3 min. The amount of freezing during the
three occasions of CS presentation provided a measure
for the acquisition of fear conditioning. After condition-
ing, the animals were removed from the conditioning
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chambers and were brought back to their home cages
30 s after the last foot shock.
On the second day, the expression of conditioned fear
expression towards context was examined (day 2, con-
text A): the animals were returned to context A. They
were placed in the test chamber for a period of 6 min
without the presentation of the CS or US. This served as
a test of conditioned fear expression towards the con-
text, in which CS-US pairings took place. The expression
of context freezing was indexed as percent time freezing
across the 6-min period.
On the third day, CS-cued conditioned fear expression
was examined (day 3, context B): the expression of con-
ditioned fear towards the CS was assessed in a novel
context B. Following an initial acclimatization period of
6 min, the CS was delivered (without subsequent shock
presentation US) and remained on for 6 min, during
which the time of conditioned freezing to the tone
stimulus was evaluated. Conditioned freezing was
expressed as percent time freezing.
Inflammatory cytokine measurements
Systemic poly(I:C) treatment in pregnant mice is known
to increase inflammatory cytokine levels in maternal and
fetal compartments [7, 15]. Here, we tested the hypoth-
esis that treatment with 1,25OHD may possibly reduce
the production of such factors after maternal poly(I:C)
treatment.
Pregnant mice on GD9 were assigned CON/VEH (n =
6), CON/VITD (n = 4), POL/VEH (n = 6), or POL/VITD
(n = 6) treatment as described above. They were killed
by decapitation 4 h post-treatment to collect maternal
blood and fetal brains. The post-treatment interval was
chosen based on previous findings showing peak cyto-
kine responses at this interval [8, 44]. Trunk blood was
collected into EDTA-containing tubes after decapitation.
Tubes were gently inverted in order to mix blood with
the EDTA. Plasma was collected upon centrifugation
and aliquots were stored at −80 °C. Two fetal brains
were collected from each dam as described before
[8, 44]. They were weighed and immediately placed in
200 μl of ice cold lysis buffer (composed of 1 cocktail
tablet—Complete Mini Protease Inhibitor Cocktail
Tablets, Roche # 11836153001—dissolved in 10 ml lysis
buffer—Roche: 04719956001), sonicated for 15 s, and then
centrifuged at 12,000 rpm for 20 min at 4 °C [8, 44]. Su-
pernatants were frozen at −80 °C until cytokine assays
were performed.
Cytokine proteins in plasma and fetal brain homoge-
nates were quantified using a customized Meso Scale
Discovery (MSD) V-Plex electrochemiluminescence
assay for mice, which allows ultralow detection of mul-
tiple cytokines in mouse plasma and supernatants [45].
In a sandwich ELISA V-plex plus, 96-well plates were
coated with primary antibodies directed against interleu-
kin IL-1β, IL-6, and TNF-α. Samples were added and cy-
tokines were detected with corresponding detecting
antibodies, which were prelabeled with SULFO-TAG™
(MSD, Rockville, MD, USA). The plates were read using
the MESO SECTOR S 600 (MSD) imager and were ana-
lyzed using MSD’s Discovery Workbench analyzer and
software package. All assays were run according to the
manufacturer’s instructions.
Vitamin D metabolite levels
Two vitamin D metabolites 24,25OHD3 and 25OHD3
were examined in the same maternal blood in which cy-
tokines were analyzed using a liquid chromatography/
tandem mass spectrometry method [46]. Therefore, this
represents samples taken 4 h post 1,25OHD administra-
tion. The assay used was insensitive to the very low
levels of 1,25OHD itself found in blood.
Statistical analysis
All data were analyzed using parametric analysis of variance
(ANOVA). A 2 × 2 (MIA×VitD treatment) ANOVA was
used to analyze the dependent measures in the elevated
plus maze, social interaction, and marble burying tests. In
the fear conditioning test, acquisition of the conditioned
fear response during the conditioning phase (day 1) was an-
alyzed using 2 × 2 × 3 (MIA ×VitD treatment × trial)
repeated-measures ANOVA, whereas conditioned freezing
towards the context (day 2) and CS-cued conditioned fear
expression (day 3) were analyzed using 2 × 2 (MIA×VitD
treatment) ANOVAs. Cytokines in the plasma of dams and
in the fetal brain tissue and vitamin D metabolites in mater-
nal blood were analyzed using a 2 × 2 (MIA×VitD treat-
ment) ANOVA as well. Following these initial ANOVAs,
Tukey’s multiple comparison test were conducted when-
ever appropriate. Statistical significance was set at P < 0.05.
All statistical analyses were performed using the statistical
software StatView (version 5.0) implemented on a PC
running the Windows XP operating system.
Results
Innate anxiety-like behavior
Neither MIA or VitD treatment alone nor their combin-
ation affected (a) time spent and (b) distance moved in
the open arms of the elevated plus maze. The relative
time spent and distance moved in the open arms (Fig. 1a,
b) were similar between the four experimental groups.
Likewise, there were no group differences in terms of
the total distance moved (Fig. 1c), suggesting that the
prenatal manipulations did not affect general locomotor
activity.
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Social interaction
In the social interaction test, the relative time spent with
an unfamiliar mouse was taken as a measure of social
approach behavior. ANOVA of this measure revealed a
significant interaction between MIA × VitD treatments
(F [2, 28] = 4.305, P < 0.05). Subsequent post hoc com-
parisons verified that the percent time spent with the
mouse was significantly (P < 0.05) decreased in POL/
VEH relative to CON/VEH mice, demonstrating
impaired social approach behavior following MIA
(Fig. 2a). Intriguingly, the MIA-induced impairment
in social approach behavior was not evident when
VitD was co-administered (Fig. 2a), suggesting that
1,25OHD blocked the negative effects of MIA on
social functions. These effects were not accompanied
by changes in general locomotor activity as indexed
by the total distance moved (Fig. 2b).
Stereotyped behavior
The percentage of marbles buried in the marble burying
test is used as an index of stereotyped behavior. As sum-
marized in Fig. 3a, this measure was markedly reduced
in POL/VEH mice relative to all other groups, suggest-
ing that MIA alters stereotyped behavior in prepubertal
offspring. Importantly, VitD co-administration fully
prevented the MIA-induced alterations in marble bury-
ing. These interpretations were supported by the
Fig. 1 Elevated plus maze behaviors in juvenile offspring who were exposed to prenatal immune challenge (POL) or prenatal vitamin D
treatment (VitD). Neither MIA or VitD treatment alone nor their combination affected (a) time spent and (b) distance moved in the open arms of
the elevated plus maze. Similarly, there were no group differences in (c) total distance moved. All values are mean ± SEM (n = 8)
Fig. 2 Social approach behavior in juvenile offspring who were exposed to prenatal immune challenge (POL) or prenatal vitamin D treatment (VitD).
a Compared with control mice poly(I:C)-treated offspring spent less time with a novel conspecific compared to an inanimate object (approaching
chance level 50%) demonstrating impaired social approach behavior (*P < 0.05). This impairment was not evident when VitD was co-administered
(#P = 0.06) suggesting VitD blocked the negative effects of MIA on social functions. b Prenatal exposures had no effects on locomotion in this test. All
values are mean ± SEM (n = 8)
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presence of a significant interaction between MIA and
VitD (F [1, 26] = 4.720, P < 0.05), and by the subsequent
post hoc comparisons confirming a significant difference
between POL/VEH and all other groups (all P < 0.05).
An examination of total distance moved revealed a
main effect of MIA (F [1, 28] = 4.808; P < 0.05), indi-
cating that poly(I:C)-exposed mice moved significantly
more in this test regardless of VitD co-treatment
(Fig. 3b).
Emotional learning and memory
The acquisition of the fear response during the condi-
tioning phase (day 1) was used as an index of emotional
learning towards aversive stimuli. The development of
conditioned fear was influenced by both MIA and VitD
treatment, as supported by the significant main effect
of MIA (F [1, 28] = 6.922, P < 0.05) and its interaction
with VitD treatment attaining statistical trend level (F
[1, 28] = 4.092, P = 0.052). Indeed, from percentage time
freezing to successive CS-US trials was significantly
lower in POL/VEH mice as compared to CON/VEH
mice (P < 0.05, Fig. 4a). The MIA-induced reduction in
fear acquisition was not evident when VitD was
co-administered (Fig. 4a), suggesting that vitamin D
blocked the effects of MIA on emotional learning.
1 day after conditioning, the animals were placed
back to the same conditioning chambers to test the ex-
pression of conditioned fear towards the context, in
which CS-US pairings took place. There were no group
differences in this measure (Fig. 4b), suggesting that the
prenatal manipulation did not affect context-cued con-
ditioned fear expression. Interestingly, however, the
expression of CS-cued conditioned fear during the tone
test, which took place 1 day after the context test, was
significantly decreased in POL/VEH mice compared to
all three other groups (Fig. 4c). ANOVA revealed a
significant interaction between MIA and VitD treatment
(F [1, 28] = 4.546, P < 0.05), and subsequent post hoc
comparisons confirmed a significant difference between
POL/VEH and CON/VEH or CON/VITD (P’s < 0.001)
and between POL/VEH and POL/VITD: P < 0.01).
Hence, maternal exposure to VitD appeared to
normalize the deficit in CS-cued conditioned fear in
MIA animals.
Cytokine measurements in maternal plasma and fetal
brains
As expected [8, 44], administration of poly(I:C) led to a
marked increase in the maternal levels of the
pro-inflammatory cytokines with a main effect of MIA for
IL-1β (F [1, 18] = 87.324, P < 0.001), IL-6 F [1, 18] = 203.262,
P < 0.001) and TNF-α F [1, 18] = 274.450, P < 0.001) (Fig. 5a).
VitD co-administration had no effect on MIA-induced ma-
ternal pro-inflammatory cytokine production (Fig. 5a).
MIA also led to a significant increase in fetal brain pro-
inflammatory cytokines, as supported by the main effect of
MIA for IL-1β (F [1, 18] = 20.13, P < 0.001), IL-6 (F [1, 18] =
46.225, P < 0.001) and TNF-α (F [1, 18] = 7.567, P < 0.05)
(Fig. 5b). Again, VitD co-administration did not affect basal
or MIA-induced elevations of pro-inflammatory cytokines in
the fetal brain (Fig. 5b).
Vitamin D metabolite levels
There was no main effect of 1,25OHD or poly(I:C) treat-
ment on maternal levels of either the major circulatory
form of vitamin D 25OHD or its inactive metabolite
24,25OHD when measured 4 h after exposure; 25OHD
Fig. 3 Marble burying behavior in juvenile offspring who were exposed to prenatal immune challenge (POL) or prenatal vitamin D treatment (VitD).
a Marble burying was markedly reduced in POL/VEH mice relative to all other groups, suggesting that MIA alters stereotyped behavior in prepubertal
offspring (*P < 0.05). VitD co-administration completely blocked this MIA-induced alteration in marble burying (*P < 0.05). b An examination of total
distance showed MIA treated mice moved significantly more in this test regardless of VitD co-treatment (*P < 0.05). All values are mean ± SEM (n = 8)
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Fig. 4 Acquisition of fear memory, association with context and fear memory behavior in juvenile offspring who were exposed to prenatal
immune challenge (POL) or prenatal vitamin D treatment (VitD). a MIA exposed mice had an impaired ability to acquire a conditioned fear
response. The percentage time freezing to successive CS-US trials was significantly lower in poly(I:C)-treated mice compared to controls
(*P < 0.05). This MIA-induced reduction in fear acquisition was not evident when VitD was co-administered suggesting that vitamin D blocked the
effects of MIA on emotional learning. b Prenatal treatment had no effect on context-cued conditioned fear expression. c Poly(I:C)-exposed mice
had reduced expression of CS-cued conditioned fear when re-exposed to the CS-tone; relative to CON/VEH (***P < 0.001) and relative to CON/VITD
or POL/VITD (**P < 0.01). Hence, maternal exposure to VitD appeared to normalize the deficit in CS-cued conditioned fear in MIA
animals. All values are mean ± SEM (n = 8)
Fig. 5 Cytokine levels in maternal blood and fetal brain 4 h post poly(I:C) exposure. a Poly(I:C) led to a marked increase in the maternal levels of all
pro-inflammatory cytokines measured (all ***P < 0.001). VitD co-administration had no effect on MIA-induced maternal pro-inflammatory cytokine
production. b Poly(I:C) also led to a significant increase in fetal brain pro-inflammatory cytokines, as supported by the main effect of MIA for IL-1β and
IL-6 (***P < 0.001) and TNF-α (*P < 0.05). Again, VitD co-administration did not affect basal or MIA-induced elevations of pro-inflammatory cytokines. All
values are mean ± SEM, (n = 6) for CON/VEH, POL/VEH, and POL/VITD groups and (n = 4) for the CON/VITD group
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and 24,25OHD concentrations (nM) in each group were
as follows: CON/VEH 29.7 ± 7.4, 21.2 ± 5.5, CON/VITD
40.3 ± 11.0, 27.2 ± 6.7, POL/VEH 35.3 ± 11.4, 20.3 ± 8.2,
and POL/VITD 36.8 ± 8.8, 23.6 ± 4.1; (P > 0.1).
Discussion
Maternal infection and/or inflammation is a recognized
environmental risk factor for developmental brain disor-
ders, including ASD [2, 5, 6, 47]. MIA in experimental
animals reproduces various behavioral phenotypes in off-
spring of potential relevance to autism [9, 19–21]. In
view of the known immunomodulatory and neuropro-
tective effects of VitD [34] and the fact that VitD defi-
ciencies have been linked to autism [26]. The present
study tested the hypothesis that maternal administration
of the active VitD hormone, 1,25OHD, would prevent
autism-relevant behavioral abnormalities in prepubertal
MIA offspring. Our data support this hypothesis by
showing that maternal VitD co-administration blocked
the emergence of the ASD-relevant deficits in social
interaction, stereotyped behavior, and emotional learning
and memory. The additional assessment of maternal and
fetal inflammatory markers, however, suggested that
these beneficial effects are unlikely to be attributable to
anti-inflammatory mechanisms.
VitD effects on MIA-induced ASD-related behaviors
Our study demonstrates that prenatal immune challenge
with poly(I:C) on GD9 disrupts social approach behavior
in prepubertal offspring. This finding corroborates the
results of previous studies reporting impaired social ap-
proach behavior in adult offspring who were subjected
to poly(I:C)-induced MIA [9, 19–21, 48]. Our findings
showing a prepubertal onset of social interaction deficits
are an important extension to this previous data in
adults. First, it increases the face validity of poly(I:C)-
based MIA models for ASD, which is characterized by
deficiencies in social interaction starting early in child-
hood. Second, these findings highlight that MIA-induced
impairments in social interaction are an early patho-
logical manifestation preceding many other behavioral
and cognitive dysfunctions in this model which do not
appear until early adulthood [49]. Such adult-onset be-
haviors include deficits in sensorimotor gating [14, 50],
selective attention [15, 16], and working memory [51].
Finally, in the context of this study, an even more im-
portant finding was that maternal treatment with the
active vitamin D hormone 1,25OHD was capable of pre-
venting this altered social behavior in juvenile MIA
offspring.
Another main finding of our study was that MIA in-
duced a decrease in the acquisition of conditioned fear
in juvenile offspring. This phenotype likely represents an
amygdala-driven deficit in associative emotional learning
[52, 53] and has been similarly observed in other models
relevant to ASD. For example, prenatal exposure to
valproic acid has been linked to an increased incidence
of ASD and is widely used to model ASD-related path-
ologies in animals [54]. Offspring from rat dams pre-
natally exposed to certain doses of valproate have very
similar deficits in the acquisition of conditioned fear
[55]. When such profound deficits in fear acquisition are
present, it is also likely to affect the expression of
learned fear [52, 53]. This was the case in our study,
where juvenile MIA offspring were found to display a
marked deficit in CS-cued conditioned fear expression.
MIA did not, however, affect the expression of condi-
tioned fear towards the context, suggesting that hippo-
campal processing of contextual cues in fear memory
was largely intact in juvenile MIA offspring [52, 53]. Im-
portantly, the MIA-induced deficits in the acquisition
and expression of CS-cued fear conditioning were
prevented by co-administration of VitD, adding further
evidence for the hypothesis that prenatal VitD treatment
in the event of MIA may be beneficial against the devel-
opment of ASD-related abnormalities.
Interestingly, previous studies using poly(I:C)-based
MIA models have found increased expression of
CS-cued conditioned fear when the offspring reached
adulthood [21]. These abnormalities are thus diametric-
ally opposite to those manifest in juvenile MIA offspring,
which show impaired acquisition and expression of
CS-cued fear conditioning. Even though we do not know
the underlying mechanisms for these divergent manifes-
tations, they may tentatively be related to altered matur-
ation of relevant neuronal substrates such as the
amygdala. Indeed, longitudinal studies in MIA models
emphasize the importance of altered brain maturation in
precipitating age-dependent behavioral and cognitive
dysfunctions [50, 51, 56].
In addition to analyzing social behavior and fear-
related learning and memory, the present study also
assessed digging behavior. To this end, a marble burying
task was performed. Juvenile poly(I:C) offspring showed
a significant reduction in stereotyped digging behavior
compared to saline-treated control offspring. This re-
duced digging was clearly not due to any MIA-induced
impairment in motor function in the poly(I:C) offspring,
because these animals were shown to be mildly hyper-
active in this task. Again importantly this abnormal ste-
reotyped behavior was prevented by maternal VitD
administration. Other authors have described poly(I:C)-
induced deficits in adult offspring with this task [19, 20].
However, when tested in adulthood, MIA offspring show
an increase in marble burying [19, 20], which is typically
interpreted as an increase in stereotyped behavior [57].
Despite this, reduced marble burying has been reported
in no less than four distinct mouse models with
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deletions in prominent genetic pathways closely associ-
ated with ASD [58]. Most experiments to date confirm
that marbles do not represent an aversive stimulus for
animals [59]. Rather, marble burying is a measure of nor-
mal stereotyped behavior in rodents; given sufficient
bedding depth, mice display stereotyped digging behav-
ior in this environment and tend to cover or bury
objects as part of this ethologically normal digging
behavior [41]. Whilst an increase is typically interpreted
as an ASD-related increase in stereotyped digging [57], a
decrease can just as easily represent an impairment in
normal stereotyped behavior. The younger age examined
here may also represent an important experimental vari-
able that has been little explored in this task. In any
case, the marble burying task provided further evidence
for the preventive potential of VitD against the develop-
ment of MIA-induced behavioral abnormalities.
Some of these behavioral abnormalities, i.e., cognitive
deficits reported in MIA juveniles may also have transla-
tional relevance to other psychiatric disorders such as
schizophrenia. However, the fact that MIA with poly(I:C)
has induced abnormalities in social interaction and cog-
nition at a more translationally relevant age, i.e., juve-
niles, together with the presence of behavioral
abnormalities not normally associated with schizophre-
nia such as altered digging behavior suggest to us that
this animal model may have greater relevance to ASD
VitD does not alter maternal or fetal inflammatory
cytokine production
In view of the known immunomodulatory effects of vita-
min D, an obvious neuroprotective mechanism explored
here was the possibility that VitD ameliorates the inflam-
matory response induced by poly(I:C). Anti-
inflammatory approaches have been successful for other
MIA-focused interventions. For instance, it has been
demonstrated that co-administration of an antibody di-
rected against one of the major inflammatory factors as-
sociated with poly(I:C)-induced MIA, IL-6, prevents
most of the behavioral deficits caused by poly(I:C). Simi-
larly, in mice where the IL-6 receptor is genetically ab-
lated many poly(I:C) induced behaviors are also blocked
[7]. More recently, a similar approach with antibodies
directed at another crucial cytokine associated with
poly(I:C)-induced MIA, IL-17a, has again shown this ap-
proach to be successful in ameliorating MIA-induced
behavioral deficits [9]. Thus, in an attempt to under-
stand how VitD might modulate poly(I:C)-induced be-
havioral abnormalities, we investigated whether VitD
might reduce the expression of key inflammatory factors.
As expected, we found large increases in the pro-
inflammatory cytokines IL-1β, IL-6, and TNFα in mater-
nal blood and fetal brains 4 h after MIA. This is in line
with previous studies demonstrating that maternal
immune challenge with poly(I:C) enhances these
pro-inflammatory cytokines in maternal sera or plasma
and fetal brain tissues at similar post-treatment intervals
[8, 14, 44]. However, co-administration of VitD had no
effect on these cytokines in any of the treatment groups,
strongly suggesting that the ASD-preventive potential of
this hormone at least in this MIA model is not primarily
related to its anti-inflammatory effects.
The immunomodulatory actions of VitD on factors
such as inflammatory cytokines are mediated via the
toll-like receptors (TLR) 2/4 [60]. For instance,
numerous studies have shown that VitD exerts its
anti-microbial actions via TLR2/4 receptors [60] and
modulates cytokine secretion from human dendritic cells
towards an anti-inflammatory environment [61]. Inflam-
matory agents upregulate both the VitD receptor and the
CYP271b which is the primary enzyme responsible for
the production of the active vitamin D hormone via a
TLR2/4 mechanism, indicating the close reciprocal feed-
back between VitD and these receptors [60, 61]. Given
that RNA viruses and artificial double-stranded RNA
constructs such as poly(I:C) act via primarily a different
toll-like pathway, i.e., TLR3, perhaps explains at least in
part why VitD failed to block MIA-induced inflammation.
What are other potential 1,25OHD-mediated
neuroprotective mechanisms in fetal brain?
Because our study does not find evidence for anti-
inflammatory actions underlying the preventive potential
of prenatal VitD administration, we consider it important
to draw attention to some other potential VitD-mediated
mechanisms that might be operating after maternal im-
mune challenge. Earlier we described how the behavioral
phenotype of poly(I:C)-exposed offspring was amelio-
rated/abolished by focusing on therapies that directly
target inflammatory cytokine production/signaling.
However, poly(I:C) can also adversely impact the early
brain via (a) impairing brain cell differentiation; (b) re-
ducing the availability of trace metals crucial for normal
brain development; (c) reducing the availability of nerve
growth factor (NGF). Importantly, as detailed below,
these same abnormalities are both reproduced by animal
models of DVD-deficiency and reversed by VitD.
In fetuses derived from mid-gestational poly(I:C)-ex-
posed dams, there is an increased subcortical prolifera-
tion [8, 50]. There are also abnormalities in cortical
laminae formation coincident with changes in cell div-
ision in the postnatal brain. In particular postnatal day
10, poly(I:C) offspring have an increase in late dividing
cells in outer layers of the cortex [62]. The DVD-
deficient brain is also hyperproliferative [33, 63, 64]. VitD
has been shown to be a potent anti-proliferative agent in
virtually every tissue examined to date. We have shown
that the addition of VitD reduces hyperproliferation in
Vuillermot et al. Molecular Autism  (2017) 8:9 Page 10 of 13
cells from DVD-deficient brains ex vivo in the form of
neurospheres [63]. Therefore, one plausible neuroprotec-
tive action of VitD may be to diminish poly(I:C)-induced
hyperproliferation in the early fetal brain.
The robust increase in IL-1β and IL-6 induced by
poly(I:C) also serves to increase peripheral synthesis of
binding proteins for trace elements such as iron and
zinc. This is an immunoprotective action reducing the
availability of these elements which are essential for the
invading pathogens [65, 66]. However, iron and zinc are
also essential for normal brain development. Therefore,
reducing iron and zinc availability may have adverse
consequences. Importantly, in other models of MIA, co-
morbid anemia produces worse outcomes [32]. In
addition, supplementation with iron prevents the ap-
pearance of several phenotypes in MIA offspring [11].
Maternal zinc supplementation also prevents the effects
of MIA on later cognitive performance in adult offspring
[12]. VitD is known to regulate the absorption of iron,
zinc, and many other trace metals from the gut [67]. In-
deed, anemia and VitD deficiency have been closely
linked for decades [68]. Most recently, VitD has been
shown to directly regulate a crucial gene in zinc trans-
port SLC30A10. Transcription of this gene was under
the direct control of SLC30A10 promoter associated
ligand-bound VDR. Moreover, the transporting protein
itself, ZnT10 was dramatically upregulated by VitD [69].
We therefore postulate that a second plausible neuropro-
tective action of VitD may be to restore the absorption of
such trace elements normally reduced by poly(I:C).
The neurotrophin NGF is reduced in the placenta 24 h
after MIA with poly(I:C) [70]. We have previously shown
that NGF is reduced in the fetal DVD-deficient brain
[33]. We and others have also demonstrated that VitD
reliably upregulates NGF in neurons. Against these back-
grounds, we postulate that a third plausible neuroprotec-
tive action of VitD may be to restore NGF to normal
levels in the poly(I:C)-treated fetal placenta and brain.
Finally, given that MIA and maternal vitamin D defi-
ciency are both risk-modifying factors for autism and
given that the distinct overlap in behavioral phenotypes
produced in the animal models of these environmental
risk factors, we addressed the issue of whether MIA in-
duces vitamin D deficiency. Obviously, if this were the
case then the corrective actions of the active vitamin D
hormone may simply be treating an MIA-induced vita-
min D deficiency. However, our results clearly show no
effect of poly(I:C) on both major circulatory measures of
vitamin D, ruling out this possibility.
Conclusions
MIA using poly(I:C) is becoming more widely used as
an animal model that produces behavioral phenotypes of
relevance to ASD. Our work here extends the face
validity of this model as we show that ASD-relevant be-
havioral alterations emerge already in prepubertal animals.
Importantly, our work strongly supports a protective role
for the hormonal form of VitD when administered during
gestation against MIA-induced changes in ASD-related
behaviors. VitD deficiency itself is increasingly being linked
with ASD [27]. Furthermore, there is initial evidence to
suggest that VitD supplementation in children with ASD
may be effective in treating this condition [71]. Unfortu-
nately, 1,25OHD as the active VitD hormone cannot be
used in pregnancy due to its potential hypercalcaemic ef-
fects on the developing fetus. However, our findings sug-
gest that future studies with the safe-to-use dietary form
of VitD, cholecalciferol, are warranted. If dietary supple-
mentation with cholecalciferol was shown to be successful
in the prevention of MIA-induced behavioral abnormal-
ities relevant to ASD (and related neurodevelopmental
disorders), then this may open new avenues for the estab-
lishment of novel therapeutic public health preventative
interventions in a similar manner to the use of folate to
prevent spina bifida.
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on various aspects of pup development. (DOCX 20 kb)
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